INmune BioINMB
About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Employees: 17
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
550% more call options, than puts
Call options by funds: $2M | Put options by funds: $308K
300% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 7
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
16% more funds holding
Funds holding: 56 [Q2] → 65 (+9) [Q3]
0.91% more ownership
Funds ownership: 23.23% [Q2] → 24.14% (+0.91%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
29% less capital invested
Capital invested by funds: $40.5M [Q2] → $28.8M (-$11.7M) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Alliance Global Partners James Molloy 0% 1-year accuracy 0 / 10 met price target | 355%upside $20 | Buy Initiated | 21 Oct 2024 |
Raymond James | 309%upside $18 | Outperform Initiated | 27 Sept 2024 |